The Four Key Trends In Pharmaceutical Alliances
Executive Summary
As the worst threats of managed care receded, the industry saw an explosion in the number of available, innovative late-stage drugs, both from biotechs and from mid-sized companies unable to sell them on their own. Genomics and combinatorial chemistry burst onto the R&D scene, generating a huge wealth of targets and compounds. The result has been a sudden return to the roots of the drug industry: finding and selling innovative branded products.